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of the 61 CIs confirmed that the draft SSA was interpreted as intended by patients, 
and assesses concepts relevant to and experienced by patients across all examined 
cancer types. Minor revisions were made to nine items to improve clarity. One 
additional item was added to ensure comprehensiveness. CONCLUSIONS: The SSA 
demonstrates strong content validity, assessing relevant CaF concepts in a man-
ner patients understand. Planned future development activities include additional 
CIs to confirm content validity of the revised, 14-item SSA in an electronic format, 
followed by an observational study for the development of scoring, item reduction, 
and psychometric validation.
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OBJECTIVES: To assess frequency and type of Patient-Reported Outcomes (PROs) in 
studies of bladder cancer. METHODS: A search of Citeline’s Trialtrove was conducted 
using the search criteria “Bladder Cancer” as the disease, drugs tested was “any”, 
trial phase was II/III, III, and IV, and included planned, ongoing and completed stud-
ies. This resulted in 182 trials. Study design included clinical trials (double-blind, 
open-label) and observational studies. Start dates ranged from 1985-2014. Trials 
were excluded if disease type was other than bladder cancer. The remaining 138 
trials were reviewed to determine prevalence and type of PROs. RESULTS: Only 
27 (7.4%) of the studies included PROs as stated in the endpoints section despite 
bladder cancer being one of the most commonly diagnosed types of cancer in the 
US, especially among men. For these 27 trials, 9 different PROs were identified, 3 of 
which were bladder cancer disease specific. A total of 39 PROs were included with a 
range of 1-2 PROs per study, an average of 1.44 PROs. Thirty-four (87%) of these PROs 
measured Health-Related Quality of Life (HRQL) and 5 (13%) were symptom-based 
measures. Within the HRQL measures, 9 (26.5%) were cancer general, 9 (26.5%) were 
specific to Bladder Cancer, 1 (3%) was generic (e.g., SF-36), and the remaining 15 
(44%) were not specified. Among the symptom measures, 3 (60%) were specific to 
bladder cancer and 2 (40%) were generic. CONCLUSIONS: Results indicate that the 
prevalence of PROs in bladder cancer trials is low compared to other cancers (e.g., 
ovarian cancer) and other diseases despite their importance in evaluating impact 
of disease and treatment benefit. The type of PRO most commonly indicated was a 
bladder cancer disease-specific measure of HRQL. Findings show the need to high-
light the value and relevance of patient-reported data to increase incorporation of 
PROs in bladder cancer trials.
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OBJECTIVES: To assess use of Patient-Reported Outcomes (PROs) in studies of 
Ovarian Cancer. METHODS: A search of Citeline’s Trialtrove was conducted using 
the search criteria of “Ovarian Cancer” as the disease, drugs tested was “any,” and 
trial phase was II/III, III, and IV. This resulted in 252 trials. Studies were excluded 
if the disease type was other than ovarian cancer. Study designs were clinical trial 
and observational studies, and both double-blind and open-label studies were 
included. Target accrual for all studies was ≥ 53. Start dates ranged from 1990 
to 2014. The remaining 189 trials were then assessed for prevalence and type of 
PROs. RESULTS: Of the 189 studies reviewed, 102 (54%) included PROs. For these 
102 trials, a total of 148 PROs were included, and an average of 1.5 PROs were 
used per study with a range of 1 to 4. A total of 15 different PROs were identified. 
One hundred twenty-six (85%) of these PROs measured Health-Related Quality of 
Life (HRQL), 10 (7%) measured QoL/Utilities, 9 (6%) measured Symptoms, 2 (1%) 
measured Activities of Daily Living and 1 (1%) was categorized as other. Within 
the HRQL measures, 35 (28%) were ovarian cancer specific measures, 27 (21%) 
were cancer general measures, 6 (5%) were cancer treatment specific, 2 (2%) were 
generic measures and 1 (1%) was chemotherapy treatment specific. The remaining 
55 (43%) HRQL endpoints were unspecified. CONCLUSIONS: PROs are included in 
ovarian cancer clinical studies approximately half the time, which is low compared 
to other disease areas. The majority of measures assess HRQL and are specific to 
ovarian cancer. Including HRQL in ovarian cancer studies can support the value of 
progression free survival to patients. PROs can be used to show the value of new 
ovarian cancer drug therapies.
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OBJECTIVES: The EORTC QLQ-C30 is a validated patient reported outcome measure 
for cancer patients but there is limited evidence on its validity in Myelofibrosis 
(MF), a rare but serious bone-marrow cancer. This study aimed to provide evi-
dence of its validity in MF. METHODS: QLQ-C30 was compared to MF specific 
measures (MF-SAF 2.0 and FACT-Lym) using trial data of MF patients (COMFORT I 
(n= 309) and COMFORT II (n= 219)). Convergent validity based on correlation analy-
sis, known group analysis based on MF specific measures using Cohen’s d effect 
size (ES) and responsiveness based on standardised response mean (SRM) were 
undertaken. RESULTS: QLQ-C30 dimensions (physical, role, emotional and social 
functioning, pain and fatigue) were strongly correlated (ρ > 0.5) with equivalent 
items/dimensions in the MF-SAF and FACT-Lym but all QLQ_C30 dimensions were 
weakly correlated (ρ < 0.3) to MF symptoms such as weight loss, itching and night 
sweats. Most QLQ-C30 dimensions were able to discriminate between MF-SAF 
(scores 0-10; 11-20; 21-30; 31-60) with better discrimination for the mild severity 
low score groups (0.2< ES< 0.7) compared to high score groups (ES< 0.2) who had 
higher severity and the FACT-Lym (scores 0-30; 31-40; 41-50; 51-60) groups. SRMs 
were < 0.2 for most QLQ-C30 dimensions including pain but > 0.2 for MF-SAF and 
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OBJECTIVES: Taste dysfunction is a common, debilitating problem for head and 
neck cancer treatment survivors (HNCTS). When taste is impaired eating is not as 
enjoyable, appetite is diminished and overall health related quality of life (HRQoL) 
is diminished. However, the extent to which taste impairment in HNCTS remains 
altered over time is not well understood. METHODS: The Ovid MEDLINE®, SCOPUS, 
and CINAHL data bases were searched for reports of HNCTS in which taste function 
was measured. Eligible studies compared taste scores baseline to up to five years 
post treatment. 3872 reports were identified in the literature search and 20 studies 
were suitable for inclusion in the final analysis. Estimates of effect size of head 
and neck cancer therapy on taste dysfunction were extracted from each study. 
A descriptive meta-analysis was conducted using Comprehensive Meta-analysis 
software (Version 2, Biostat, Englewood, NJ). RESULTS: The meta-analysis included 
data on 1526 subjects. The sample was predominantly young in age (mean age is 
59.11 years) and 66.8% male. Head and neck cancer treatment survivors reported 
statistically significantly worse taste scores 6 months or longer after completing all 
cancer treatment. The summary effect for the standard measure difference between 
pretreatment and post-treatment taste scores was 0.331 (p= < 0.001). The sample 
was highly heterogeneous in terms of country, tumor site, and therapy, so a random 
effects model was chosen for data analysis. Heterogeneity testing supported this 
decision (Q= 82.08, df 18, p < 0.001). CONCLUSIONS: Assessment of HRQoL in HNCTS 
should include questions on taste function. With the global increase in HPV related 
head and neck cancers, the pool of treatment survivors is expected to increase over 
the next decade. The Taste dysfunction is a long-term complication for HNCTS and 
clinicians should screen survivors for this sensory dysfunction.
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OBJECTIVES: The US Food and Drug Administration (FDA) did not approve any 
PRO label claims for cancer treatments between 2006 and 2010. In December 2009, 
the agency published guidance on the use of PROs to support label claims, and 
in 2012 the Center for Medical Technology Policy (CMTP) called for all prospec-
tive comparative studies of oncology drugs in adults to include PRO measures. 
The current study sought to identify how many PRO claims have been approved 
since the publication of these documents, to consider the challenges for sponsors 
seeking such claims, and offer solutions to these challenges. METHODS: The FDA 
website was searched for approvals of hematology and oncology drugs 2010–2014. 
The most recently approved labels of eligible products and drug approval packages 
were reviewed for comments on PRO data. RESULTS: Of 64 drug labels suitable 
for review, two had PRO efficacy claims: ruxolitinib (myelofibrosis) was claimed to 
improve symptoms, as measured by the Myelofibrosis Symptom Assessment Form; 
abiraterone acetate (prostate cancer) was claimed to improve pain, as measured 
by the Brief Pain Inventory (BPI-SF). For crizotinib (NSCLC), PROs were used to sup-
port adverse event reporting (vision disorders). The label for brentuximab stated 
that no improvement in patient-reported symptoms for either indication (Hodgkin 
lymphoma and anaplastic large cell lymphoma) had been established. A further 
12 labels stated that there were no data to demonstrate improvement in disease-
related symptoms. CONCLUSIONS: This review demonstrates the emergence of 
PRO label claims for oncology products, despite the recent FDA and CMTP guidance 
PRO data are infrequently documented in FDA-approved oncology labels. Labels 
increasingly specify when there is an absence of symptom data e.g. brentuximab, 
carfilzomib, marking a shift in FDAs expectations. Sponsors face challenges such as 
a lack of validated tumor-specific instruments. A strategic four-step PRO endpoint 
development process provides a way forward.
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OBJECTIVES: Cancer-related fatigue (CaF) is a common symptom of cancer and one 
that can be burdensome to patients. It is possibly under-reported due to its complex 
origins, inconsistent definitions and assessment methods. In recent years, no exist-
ing measures have been accepted by the US Food and Drug Administration (FDA) to 
support labeling claims in CaF. The Patient-Reported Outcomes of Fatigue in Cancer 
(PROOF-C) Consortium have developed the Symptom Severity Assessment (SSA), a 
patient-reported outcome (PRO) measure of CaF to be aligned with FDA expectations 
as part of the FDA’s Drug Development Tool (DDT) Qualification Program. METHODS: 
In total 91 open-ended concept elicitation (CE) interviews were conducted among 
eight cancer types to spontaneously elicit the patient experience of CaF. Items 
were generated based on qualitative, thematic analysis of verbatim transcripts and 
with input from a clinical expert. Subsequently, 61 cognitive interviews (CIs) were 
conducted with patients in six cancer types, wherein a “think-aloud” process and 
targeted debriefing questions were used to assess concept relevance and patients’ 
understanding of the instructions, items, and response options. RESULTS: CE data 
supported the development of a draft, 13-item SSA, measuring eight symptoms of 
CaF, with a 24-hour recall period and an 11-point numeric rating scale. The results 
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impact on how patients feel or function, which summarizes health-related quality 
of life (HRQoL). Contemporary mCRPC therapies have shown survival improvements 
and varying HRQoL impacts. In order to understand the true burden of illness (BOI) 
in these patients and how it is impacted by treatment, it is critical to understand 
how patient-centered outcomes are measured and interpreted. METHODS: This lit-
erature review identified MEDLINE publications reporting on HRQoL (including pain) 
in ≥ 50 mCRPC patients using predefined search terms: prostate, prostate cancer, 
castrate- or hormone-resistant, hormone refractory, androgen-independent, andro-
gen independence and quality of life, HRQoL, pain, bone or cancer-related pain, 
fatigue, and weight loss. RESULTS: Forty-four mCRPC studies were identified that 
met prespecified criteria and included 14 unique HRQoL instruments. Important 
HRQoL issues for mCRPC patients included pain, nausea/vomiting, and insomnia. 
The most commonly used measures were EORTC QLQ-C30, FACT-P, and the BPI/
McGill pain questionnaires. Most of these instruments were not specifically devel-
oped for mCRPC patients and may not comprehensively capture symptoms impor-
tant to this population. Further, identified studies did not use consistent definitions 
of clinically meaningful differences. Since 2010, using a variety of instruments in 
pivotal studies, 3 treatments (mitoxantrone, estramustine phosphate and doc-
etaxel, and cabazitaxel) had no statistically significant impacts on HRQoL or pain, 
whereas 4 other treatments (abiraterone, enzalutamide, radium-223, and sipuleu-
cel-T) reported statistically significant benefits for HRQoL or pain. CONCLUSIONS: 
HRQoL is an important complement to survival and other clinical endpoints to best 
understand treatment benefit in mCRPC. To give context to the relative impact of 
treatments on HRQoL, it is critical to understand the underlying BOI in this patient 
population and to standardize methods for measuring and quantifying the assess-
ment of HRQoL in mCRPC.
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OBJECTIVES: There is no evidence about the appropriateness of the EQ-5D (a 
generic preference-based measure of health) in Myelofibrosis (MF), a rare but seri-
ous bone-marrow cancer. This study aimed to provide psychometric evidence of its 
appropriateness. METHODS: Convergent validity and responsiveness of the EQ-5D 
was assessed by comparing it to a condition-specific measure, the MF Symptom 
Assessment Form (MFSAF) in 48 patients with MF with repeated measurement over 
48 weeks using data from the ROBUST study. Convergent validity was based on 
correlation analysis between EQ-5D utility scores and dimensions (mobility, usual 
activities, self-care, pain/discomfort and anxiety/depression) and MFSAF total score 
and symptoms (pain, early satiety, night sweats, itching and bone or muscle pain). 
Responsiveness was based on change in EQ-5D compared to change in MFSAF using 
standardized response mean (SRM) and Cohen’s effect size (ES). Moderate to strong 
correlations (rho> |0.3|) and comparable SRM and ES would indicate that EQ-5D 
was appropriate. RESULTS: EQ-5D had poor associations with key symptoms in MF 
(rho< |0.3|), except for the ‘pain/discomfort’ and ‘anxiety/depression’ health dimen-
sions (rho> |0.4|). SRM and ES at week 4 for EQ-5D was 0.270 and 0.343 compared to 
SRM and ES of 0.911 and 0.826 for the MF-SAF. A large proportion (15.56%) reported 
no problems in EQ-5D dimensions at baseline. The MFSAF total score did not show 
comparable ceiling effect (4.76%). There was however some indication of ceiling 
effect for some of the individual dimension of the MFSAF indicating that patients 
in this sample did not all have the common MF symptom. CONCLUSIONS: This 
exploratory analysis suggests that the EQ-5D’s ability to capture the effect of key 
symptoms in MF is limited to pain rather than the specific MF symptoms such as 
night sweats and itchiness. However, results of this analysis need to be interpreted 
with caution due to the small number of patients.
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OBJECTIVES: The aim of this study was to evaluate the associations between quality 
of life (QoL) domains and frequency of readmission to hospitals for different cancer 
patients. A secondary aim was to observe if the increased number of outpatient 
clinic admissions resulted an increased number of hospitalizations. METHODS: 
We evaluated QoL (EORTC QoL Questionnaire-C30) and hospital admissions in 
350 patients with lung, breast, hematological, head and neck, colorectal, gastric, 
gynecological, and prostate cancers. The outpatient clinic admission and hospi-
talization data for each patient within 1-year of QoL assessment was obtained 
from the hospital finance database. Statistical analyses used nonparametric correla-
tion coefficients to flag associations (r> 0.3 and p< 0.05) between overall, functional 
or symptom scales and number of hospitalizations or outpatient clinic admis-
sions. RESULTS: QoL domains associated with readmissions within 3 months were, 
emotional functioning (r= 0.42, p= 0.003) and global health status (r= 0.51, p< 0.001) for 
gastric cancers. For readmissions within 1 year they were nausea/vomiting symp-
tom scales (r= 0.44, p= 0.002) for colorectal cancer and global health status (r= 0.46, 
p= 0.001) for gastric cancers. Constipation (r= 0.32, p= 0.025) and nausea/vomiting 
scales (r= 0.32, p= 0.024) for breast cancers were associated with hospitalizations 
within 3 months. Diarrhea symptom scale (r= 0.35, p= 0.013) for colorectal cancers 
and appetite loss scale (r= 0.55, p= 0.016) for prostate cancers were associated with 
hospitalizations within 1 year. In general, number of hospitalizations and admis-
sions were not significantly correlated except for the head and neck cancers (r= 0.32, 
p= 0.022, within 1 year). CONCLUSIONS: Several quality of life domains might be 
associated with hospital admissions and hospitalizations. Although they may not 
always reflect causal relations, these QoL evaluations may be used to flag possible 
increases in contact with health care system and to timely notify the patient or their 
relatives of this possibility. Increased number of clinic visits does not necessarily 
result in increased hospitalizations for most cancer types.
FACT Lym MF symptoms. A large proportion (n> 50%) reported no problems (ceiling 
effects) in QLQ-C30 dimensions (nausea/vomiting, constipation/diarrhoea). There 
was some evidence of ceiling effects in MF symptoms in COMFORT II due to miss-
ing data which affects the analysis. CONCLUSIONS: QLQ-C30 reflected functional 
and fatigue effects of MF but was less associated with MF specific symptoms such 
as itching and night sweats which are important MF symptoms. The QLQ-C30 pain 
dimension showed less responsiveness than the MF specific pain dimensions. 
QLQ-C30 dimensions related to constipation and diarrhoea were less relevant in 
this population than has been found in other cancer populations.
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OBJECTIVES: Psychometric analyses to derive a health state classification system 
in multiple myeloma using the European Organization for Research and Treatment 
of Cancer Core Quality of Life Questionnaire (EORTC QLQ-30) were used to esti-
mate a preference-based measure for health state utility derivation (Rowen et al. 
2011). This study sought to apply a modified Rowen framework to identify EORTC 
QLQ-30 and the breast module (QLQ-BR23) items amenable to valuation to esti-
mate a preference-based measure in metastatic breast cancer (MBC). METHODS: 
Exploratory factor analysis, Rasch analysis and other psychometric analyses 
were undertaken on the 53 item EORTC tools using baseline Phase 3 clinical trial 
data on 1063 patients with MBC to identify items amenable to valuation. Criteria 
for item identification were: factor loading > 0.4; < 50% of respondents at ceil-
ing/floor; mean square fit statistics between 0.5 and 1.5; and ordered category 
response. RESULTS: Nine dimensions were identified on the EORTC dataset via 
exploratory factor analysis. Potential items, stratified by dimension, deemed useful 
for valuation include: physical (QLQ-30 items 1, 2, 6, 7, 27 and QLQ-BR23 item 6), 
cognitive/emotional (QLQ-30 items 21, 22, 23 and 24), self-image (QLQ-BR23 items 
9, 10, 11 and 12), breast symptoms (QLQ-BR23 item 20), fatigue/sleep disturbance 
(QLQ-30 items 10, 12 and 18), arm pain (QLQ-BR23 item 17), and general pain 
(QLQ-30 item 9). Items related to gastrointestinal and sexual symptoms were not 
considered due to the measurement criteria. CONCLUSIONS: Twenty of 53 items 
suitable for valuation were identified over seven dimensions of the EORTC QLQ-
30 and QLQ-BR 23. Items that did not meet the specified criteria for inclusion 
may be utilized for health state derivation if they represent clinically significant 
components of MBC. Results of the created health state classification system for 
valuation and derivation of a preference-based measure for metastatic breast 
cancer will be presented.
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OBJECTIVES: Two effective therapies, enzalutamide and AbP, emerged simulta-
neously for treating patients with mCRPC that has progressed on or after doc-
etaxel (post-chemotherapy setting) and yet are not compared head-to-head. 
This study aims to assess the comparative effectiveness of these treatments on 
QoL. METHODS: A systematic literature review of MEDLINE, Embase, Cochrane, 
and controlled trials registries was conducted to identify all evidence on the treat-
ment effect of enzalutamide and AbP on patients’ QoL in the post-chemotherapy 
setting. Since there are no trials directly comparing these treatments, an adjusted 
indirect comparison (Bucher et al. 1997) was performed on improvement and time 
to deterioration in FACT-P total score and subdomains. Results are expressed as odds 
ratio or hazard ratio with corresponding 95% confidence intervals (CIs). RESULTS: 
Two randomized, placebo-controlled, Phase III studies (AFFIRM and COU-AA-301) 
were identified and included in the analysis. The studies had similar study popula-
tions and designs but used different comparators (placebo in AFFIRM; prednisone in 
COU-AA-301) which were assumed to be similar. The same pre-specified criteria for 
clinically meaningful improvement and deterioration in FACT-P outcomes were used 
in both studies (Cella et al. VIH2009). Compared with AbP, enzalutamide significantly 
increased the likelihood of QoL improvement on the FACT-P total score (odds ratio 
[95% CI]: 1.94 [1.15; 3.27]), functional wellbeing (1.85 [1.09; 3.14]), and prostate cancer 
subscales (PCS) (1.79 [1.10; 2.90]). Enzalutamide significantly decreased the risk of 
QoL deterioration in FACT-P total score (hazard ratio [95% CI]: 0.72 [0.54; 0.95]) and 
PCS (0.75 [0.58; 0.98]) vs. AbP. CONCLUSIONS: The impact of enzalutamide on QoL 
in the post-chemotherapy setting compares favorably with AbP, with significantly 
higher odds of QoL improvement and significant delay in QoL deterioration, subject 
to study assumptions. The adjusted indirect comparison method can shed light 
on relative benefits of effective therapies that have not been formally compared.
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OBJECTIVES: Survival is the predominant measure of metastatic castration-resist-
ant prostate cancer (mCRPC) treatment benefit, but it does not account for the 
